February 5, 2021

Alverno Laboratories has announced changes regarding prenatal risk assessment testing, specifically QUAD screens and Maternal Serum AFP, effective January 4, 2021. These tests will now be sent to ARUP Laboratories due to the need for robust statistical data that Alverno Laboratories cannot sustain independently. To ensure accurate analysis, detailed patient history information is required, and a Prenatal Risk Assessment Form is provided on page 2 of the document and available on the Alverno website under the "Provider Forms" tab. It's emphasized that all questions on the form must be answered for timely and accurate risk analysis, as unanswered questions will cause testing delays.